title: A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis.
abstract: OBJECTIVE
  This study was conducted to compare overall survival (OS) in patients presenting with isolated hepatic metastases with that of patients with synchronous metastatic disease to the liver and sarcomatosis on a background of gastrointestinal stromal tumours (GISTs).
  
  
  METHODS
  Patients presenting with metastatic GISTs during 1999-2009 were identified. Survival outcomes were compared between groups.
  
  
  RESULTS
  Of the 193 patients with GISTs, 43 patients presented with isolated hepatic metastases and 16 presented with synchronous metastases to the liver and sarcomatosis. Thirteen patients with metastases to the liver and sarcomatosis underwent surgery, and 34 patients with metastatic disease solely to the liver underwent hepatic resection. The proportion of patients treated with preoperative tyrosine kinase inhibitor (TKI) therapy was similar in both groups. Similar OS was observed in both groups (isolated liver metastases group: 40.5 months; liver metastases and sarcomatosis group: 28.7 months; P = 0.620).
  
  
  CONCLUSIONS
  Overall survival in patients with GIST and metastatic disease to the liver and sarcomatosis is similar to that in patients with isolated metastatic liver disease. Although patients with a greater disease burden might be expected to show worse survival, these data do not reflect this assumption.
authors: Department of Sarcoma Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
authors: Sebastian G
authors: SG
authors: de la Fuente
authors: Jeremiah L
authors: JL
authors: Deneve
authors: Colin M
authors: CM
authors: Parsons
authors: Jonathan S
authors: JS
authors: Zager
authors: Anthony P
authors: AP
authors: Conley
authors: Ricardo J
authors: RJ
authors: Gonzalez
mesh_terms: D000368:Aged; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D005260:Female; D005431:Florida; D005770:Gastrointestinal Neoplasms / Q000201:enzymology / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D046152:Gastrointestinal Stromal Tumors / Q000201:enzymology / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D006498:Hepatectomy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000201:enzymology / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D012189:Retrospective Studies; D012509:Sarcoma / Q000201:enzymology / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D062606:Tertiary Care Centers; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases